Candida auris: The Emerging Fungal Threat in U.S. Healthcare

• by Shimanta Das
• August 12, 2026

Candida auris, a drug-resistant fungus first identified in the United States in 2016, has rapidly become a major public health concern. This pathogen poses a significant threat, particularly to individuals with weakened immune systems, prolonged hospital stays, ICU admissions, or those on ventilators or central lines. In severe cases, the infection can enter the bloodstream, leading to sepsis, organ failure, and life-threatening complications. The CDC warns that people without major medical risk factors, including visitors and healthcare workers who follow proper hygiene, rarely become infected, but the highest risk remains among hospitalized patients receiving complex care.

Symptoms of Candida auris infection vary depending on the site of infection, but common warning signs include persistent fever, chills, low blood pressure, rapid heart rate, and low body temperature. Because these symptoms mimic many other serious illnesses, laboratory testing is essential for accurate diagnosis. Health officials emphasize that rapid detection, screening programs, and strict infection-control measures in hospitals and long-term care facilities are critical to preventing its spread. The fungus can persist on a patient’s skin or body for extended periods, even without symptoms, allowing silent transmission.

As of 2026, twenty-three states have reported at least one screening case, with the fungus spreading across every major U.S. region. The majority of cases have been in males and occurred in acute care facilities. This fungus is challenging to treat because it is developing resistance to commonly used antifungal drugs, making prevention even more vital. The emergence of Candida auris underscores the urgent need for enhanced surveillance and robust infection prevention protocols to protect vulnerable patients and curb its spread.